Abstract:Abstract Inflammasomes are multi-protein signalling scaffolds that assemble in response to invasive pathogens and sterile danger signals to activate inflammatory caspases (1/4/5/11), which trigger inflammatory death (pyroptosis) and processing and release of pro-inflammatory cytokines 1,2 . Inflammasome activation contributes to many human diseases, including inflammatory bowel disease, gout, type II diabetes, cardiovascular disease, Alzheimer’s disease, and sepsis, the often fatal response to systemic infection 3–6 . The recent identification of the pore-forming protein gasdermin D (GSDMD) as the final pyroptosis executioner downstream of inflammasome activation presents an attractive drug target for these diseases 7–11 . Here we show that disulfiram, a drug used to treat alcohol addiction 12 , and Bay 11-7082, a previously identified NF-κB inhibitor 13 , potently inhibit GSDMD pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Moreover, disulfiram, administered at a clinically well-tolerated dose, inhibits LPS-induced septic death and IL-1β secretion in mice. Both compounds covalently modify a conserved Cys (Cys191 in human and Cys192 in mouse GSDMD) that is critical for pore formation 8,14 . Inflammatory caspases employ Cys active sites, and many previously identified inhibitors of inflammatory mediators, including those against NLRP3 and NF-κB, covalently modify reactive cysteine residues 15 . Since NLRP3 and noncanonical inflammasome activation are amplified by cellular oxidative stress 16–22 , these redox-sensitive reactive cysteine residues may regulate inflammation endogenously, and compounds that covalently modify reactive cysteines may inhibit inflammation by acting at multiple steps. Indeed, both disulfiram and Bay 11-7082 also directly inhibit inflammatory caspases and pleiotropically suppress multiple processes in inflammation triggered by both canonical and noncanonical inflammasomes, including priming, puncta formation and caspase activation. Hence, cysteine-reactive compounds, despite their lack of specificity, may be attractive agents for reducing inflammation.

Mechanism of Gasdermin D Recognition by Inflammatory Caspases and Their Inhibition by a Gasdermin D-derived Peptide Inhibitor

Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death

Gasdermin D is an Executor of Pyroptosis and Required for Interleukin-1Β Secretion

Caspase-1 Engages Full-Length Gasdermin D Through Two Distinct Interfaces That Mediate Caspase Recruitment and Substrate Cleavage

Structures of Gasdermin-D C-Terminal Domain Reveal Mechanisms of Autoinhibition

Structures of the Gasdermin D C-Terminal Domains Reveal Mechanisms of Autoinhibition.

Crystal Structures of the Full-Length Murine and Human Gasdermin D Reveal Mechanisms of Autoinhibition, Lipid Binding, and Oligomerization.

Pore-forming activity and structural autoinhibition of the gasdermin family

Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling

Pyroptosis inhibiting nanobodies block Gasdermin D pore formation

Gasdermin D:The killer protein performs cell pyroptosis

Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation

Gasdermin D Serves As a Key Executioner of Pyroptosis in Experimental Cerebral Ischemia and Reperfusion Model Both in Vivo and in Vitro.

Recognition of Gasdermins by Proteases

GSDMB promotes non-canonical pyroptosis by enhancing caspase-4 activity.

Gasdermin D-mediated pyroptosis: mechanisms, diseases, and inhibitors

New insights into Gasdermin D pore formation

Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D

Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores

Gasdermin D in pyroptosis

Porcine Gasdermin D is a Substrate of Caspase-1 and an Executioner of Pyroptosis